652 related articles for article (PubMed ID: 27465105)
1. Prospective clinical trial of Intravitreal aflibercept treatment for PolypoIdal choroidal vasculopathy with hemorrhage or exudation (EPIC study): 6 month results.
Kokame GT; Lai JC; Wee R; Yanagihara R; Shantha JG; Ayabe J; Hirai K
BMC Ophthalmol; 2016 Jul; 16():127. PubMed ID: 27465105
[TBL] [Abstract][Full Text] [Related]
2. Short-term efficacy of intravitreal aflibercept in treatment-naive patients with polypoidal choroidal vasculopathy.
Inoue M; Arakawa A; Yamane S; Kadonosono K
Retina; 2014 Nov; 34(11):2178-84. PubMed ID: 25046397
[TBL] [Abstract][Full Text] [Related]
3. Aflibercept Treatment for Neovascular Age-related Macular Degeneration and Polypoidal Choroidal Vasculopathy Refractory to Anti-vascular Endothelial Growth Factor.
Moon DRC; Lee DK; Kim SH; You YS; Kwon OW
Korean J Ophthalmol; 2015 Aug; 29(4):226-32. PubMed ID: 26240506
[TBL] [Abstract][Full Text] [Related]
4. Six-month results of intravitreal aflibercept injections for patients with polypoidal choroidal vasculopathy.
Hosokawa M; Shiraga F; Yamashita A; Shiragami C; Ono A; Shirakata Y; Kimura S; Shiode Y; Kawata T; Hosogi M; Fujiwara A; Morizane Y
Br J Ophthalmol; 2015 Aug; 99(8):1087-91. PubMed ID: 25712826
[TBL] [Abstract][Full Text] [Related]
5. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab.
Saito M; Kano M; Itagaki K; Oguchi Y; Sekiryu T
Retina; 2014 Nov; 34(11):2192-201. PubMed ID: 25077530
[TBL] [Abstract][Full Text] [Related]
6. Preliminary results of aflibercept in treatment-naive choroidal neovascularization of wet age-related macular degeneration.
Gambon R; Barthelmes D; Amstutz C; Fleischhauer J; Kurz-Levin M; Zweifel S
Klin Monbl Augenheilkd; 2014 Apr; 231(4):423-6. PubMed ID: 24771183
[TBL] [Abstract][Full Text] [Related]
7. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T
Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
[TBL] [Abstract][Full Text] [Related]
8. One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy.
Yamamoto A; Okada AA; Kano M; Koizumi H; Saito M; Maruko I; Sekiryu T; Iida T
Ophthalmology; 2015 Sep; 122(9):1866-72. PubMed ID: 26088619
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal Tissue Plasminogen Activator, Ranibizumab, and Gas Injection for Submacular Hemorrhage in Polypoidal Choroidal Vasculopathy.
Kitagawa Y; Shimada H; Mori R; Tanaka K; Yuzawa M
Ophthalmology; 2016 Jun; 123(6):1278-86. PubMed ID: 26949121
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of intravitreal injection of aflibercept in neovascular age-related macular degeneration with or without choroidal vascular hyperpermeability.
Hata M; Oishi A; Tsujikawa A; Yamashiro K; Miyake M; Ooto S; Tamura H; Nakanishi H; Takahashi A; Yoshikawa M; Yoshimura N
Invest Ophthalmol Vis Sci; 2014 Nov; 55(12):7874-80. PubMed ID: 25395483
[TBL] [Abstract][Full Text] [Related]
11. AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY: As Needed Versus Fixed Interval Dosing.
Inoue M; Yamane S; Taoka R; Arakawa A; Kadonosono K
Retina; 2016 Aug; 36(8):1527-34. PubMed ID: 26710307
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of subretinal vessel location in polypoidal choroidal vasculopathy (PCV) and response of hemorrhagic and exudative PCV to high-dose antiangiogenic therapy (an American Ophthalmological Society thesis).
Kokame GT
Trans Am Ophthalmol Soc; 2014 Jul; 112():74-93. PubMed ID: 25646029
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
14. ONE-YEAR RESULTS OF INTRAVITREAL AFLIBERCEPT FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Hara C; Sawa M; Sayanagi K; Nishida K
Retina; 2016 Jan; 36(1):37-45. PubMed ID: 26383709
[TBL] [Abstract][Full Text] [Related]
15. Fluctuations in Pigment Epithelial Detachment and Retinal Fluid Using a Bimonthly Treatment Regimen with Aflibercept for Neovascular Age-Related Macular Degeneration.
Zinkernagel MS; Wolf S; Ebneter A
Ophthalmologica; 2016; 235(1):42-8. PubMed ID: 26540259
[TBL] [Abstract][Full Text] [Related]
16. Prognosti implications of pigment epithelial detachment in bevacizumab (avastin)-treated eyes with age-related macular degeneration and choroidal neovascularization.
Freeman WR; Kozak I; Yuson RM; Nigam N; Cheng L; Mojana F
Retina; 2011 Oct; 31(9):1812-8. PubMed ID: 21866073
[TBL] [Abstract][Full Text] [Related]
17. INTRAVITREAL AFLIBERCEPT FOR CHOROIDAL NEOVASCULARIZATION DUE TO AGE-RELATED MACULAR DEGENERATION UNRESPONSIVE TO RANIBIZUMAB THERAPY.
Sarao V; Parravano M; Veritti D; Arias L; Varano M; Lanzetta P
Retina; 2016 Apr; 36(4):770-7. PubMed ID: 26398691
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of outer retinal tubulations in eyes switched from intravitreal ranibizumab to aflibercept for treatment of exudative age-related macular degeneration.
Massamba N; Dirani A; Butel N; Fardeau C; Bodaghi B; Ingram A; Lehoang P
Graefes Arch Clin Exp Ophthalmol; 2017 Jan; 255(1):61-67. PubMed ID: 27397583
[TBL] [Abstract][Full Text] [Related]
19. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
[TBL] [Abstract][Full Text] [Related]
20. Subfoveal Choroidal Thickness during Aflibercept Therapy for Neovascular Age-Related Macular Degeneration: Twelve-Month Results.
Koizumi H; Kano M; Yamamoto A; Saito M; Maruko I; Sekiryu T; Okada AA; Iida T
Ophthalmology; 2016 Mar; 123(3):617-24. PubMed ID: 26686967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]